Well-funded and with a stellar pipeline, TESARO is an up and coming Boston-based oncology biotech ready to launch their two first products in the European market in 2017.
Orlando, we understand your background in the biotech industry is with Amgen. After a career with the biggest of the biotechs, what was it that convinced you to join TESARO?
"There are certainly a lot of strong biotech hubs across Europe, and at the beginning we considered locations in the UK, the Netherlands and Switzerland as the three broad options."
